Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated response accurately asserts that the supplied estradiol/norethindrone acetate label addresses increased risks for cardiovascular disorders, probable dementia, breast cancer, and endometrial cancer via the Boxed Warning and Warnings/Contraindications sections, consistent with the provided label excerpts.
Category Scores
Accurate Statements
Cardiovascular disorders: label supports/warns about increased risks of stroke and DVT with estrogen-alone and increased risks of PE, DVT, stroke, and MI with estrogen plus progestin; boxed warning also states not to use for prevention of cardiovascular disease.
Boxed Warning (Cardiovascular Disorders and Probable Dementia); Warnings and Precautions (5.1).
Probable dementia: label supports/warns about increased risk with WHIMS for estrogen-alone and estrogen plus progestin, and states not to use for prevention of dementia.
Boxed Warning (Probable Dementia); Warnings and Precautions (5.3); Clinical Studies (14.6).
Breast cancer: label supports/warns about increased risk of invasive breast cancer with estrogen plus progestin and contraindicates use in women with breast cancer or history of breast cancer.
Boxed Warning (Breast Cancer); Warnings and Precautions (5.2); Contraindications (Section 4).
Endometrial cancer: label supports/warns that unopposed estrogens increase endometrial cancer risk in women with a uterus and that adding a progestogen reduces risk of endometrial hyperplasia; diagnostic measures are recommended for persistent/recurrent abnormal bleeding.
Boxed Warning (Endometrial Cancer); Warnings and Precautions (5.2).
The response characterizes these diseases as key risks/warnings rather than approved indications, and notes the label advises against use for prevention of cardiovascular disease or dementia.
Boxed Warning statements regarding prevention (cardiovascular disease and dementia) and the structure of these diseases as risks within Boxed Warning/Warnings/Contraindications rather than indications.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response only evaluates whether the label addresses risks/warnings and contraindications for the specified conditions; it does not provide dosing, patient-specific recommendations, or additional unsupported risk claims beyond those described in the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
If expanding beyond risk/warning characterization, quote or paraphrase the exact wording from the full product label text for each referenced section to avoid reliance on section-number plausibility.